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3 Research integrity: clinical trials transparency 
Summary
Selective non-publication of the results of research distorts the published evidence base 
and is a threat to research integrity. In the case of clinical trials, non-publication of results 
means that information on the efficacy of new drugs or other medical interventions 
cannot be used. Falling short on ‘clinical trials transparency’ in this way presents risks 
to human health, contributes to research wastage and means that clinical decisions are 
made without access to all the available evidence.
A range of UK and EU rules and guidelines are now in force to improve clinical trials 
transparency, in terms of tackling non-registration, non-reporting and mis-reporting. 
However, despite these rules, around half of clinical trials are currently left unreported, 
clinical trial registration is not yet universal in the UK, and reported outcomes do not 
always align with the original study proposal.
Our predecessor Committee concluded in 2013 that it had “not been impressed” by the 
Government’s efforts to resolve the problem of un-registered, non-reported and mis-
reported clinical trials. We believe that while there have been some improvements there 
is still much more to be done. The Ebola epidemic prompted political attention in the 
UK to the risks to public health of non-publication of clinical trial results, with the then 
Prime Minister David Cameron making commitments to clinical trials transparency 
in 2015. Since then, progress has slowed in the UK at a political level. Clinical trials 
transparency is as much a question of political will as it is a technical issue.
The Health Research Authority (HRA) has been explicitly responsible for “promoting 
research transparency” as part of its statutory objectives since 2014, but this does not 
appear to have brought about significant change in this area over the last four years. 
The Government should ask the HRA to publish, by December 2019, a detailed strategy 
for achieving full clinical trials transparency, with a clear deadline and milestones for 
achieving this. The performance of the HRA should then be explicitly measured on this 
basis through its annual report.
Non-compliance with reporting rules is not currently documented by public bodies 
on a trial-by-trial basis. Official publication of such information would expose where 
there are weaknesses in compliance and where best practice within the sector could be 
found and shared. The HRA should be provided with funding to establish a national 
programme to audit clinical trials transparency, including the publication of a single 
official list of which UK trials have published results and those which are due to but 
have not. In the first instance this should focus on providing information on whether 
any results have been published in an academic journal following global best practice, 
building on the automated methods already developed by others.
We are disappointed that the HRA does not believe it can secure funding for a more 
comprehensive form of audit focusing on mis-reporting of trials and does not see this as 
a priority. Even if the cost of fully assessing reported trial outcomes against the original 
specification in the application for ethical approval amounts to £2.4m per year, as the 
HRA suggested in evidence to us, this is a small price to pay compared with the sums of 
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money involved in policy decisions that draw on clinical trials evidence. We recommend 
that the HRA undertake further work to determine an accurate figure for the cost of 
such an audit and prepare a funding proposal for the Government to consider.
Meanwhile, the HRA appears to be reluctant to enforce its transparency rules, or to 
make previous compliance with transparency legislation a pre-requisite for ethical 
approval of future trials. As a result, there are currently no sanctions imposed on 
sponsors or investigators who fail to comply with HRA rules, or even on those who 
fail to respond to the HRA when their non-compliance is queried. The HRA should 
introduce a system of sanctions to drive improvements in clinical trials transparency, 
such as withdrawing favourable ethical opinion or preventing further trials from taking 
place, and the Government should consult specifically on whether to provide the HRA 
with the statutory power to fine sponsors for non-compliance.
Compliance with transparency rules varies by sponsor—while pharmaceutical 
companies have good rates of reporting within a reasonable timeframe, the picture is 
much more mixed for universities. It is particularly disappointing that trusted bodies 
such as Public Health England and a range of NHS Foundation Trusts are also failing 
to report results from clinical trials. Public trust in medicine could easily be eroded by 
failures in clinical trials transparency from such important parts of the health system. 
Public Health England should write to us with an explanation and the steps it will take 
to correct this.
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1 Introduction
1. In July 2018 we published our Report on research integrity, exploring a range of 
threats to the rigour, accuracy, honesty and transparency of research. These included 
‘fraud, fabrication and plagiarism’ and a range of ‘questionable research practices’, any 
of which can lead to unreliable research being published.1 However, during that inquiry 
we were told that selective non-publication of research results—or ‘publication bias’—was 
also a threat to the integrity of the evidence base and should be considered as part of our 
work.2 Indeed, the Concordat to Support Research Integrity produced by Universities UK 
and signed by the higher education funding councils and research councils states that 
“refusing to publish negative research findings” is “harmful to the reputation and quality 
of UK research, and to the research record”.3
2. Further exploration of the issue of publication bias during our inquiry into research 
integrity revealed an opportunity for us to follow up on work by our predecessor 
Committee from 2013 on clinical trials.4 One of the issues our predecessor explored 
was the extent to which the results of clinical trials of drugs, vaccines and other health 
interventions are made available to scientists, clinicians and members of the public—often 
referred to as ‘clinical trials transparency’.5 Our predecessor Committee noted “long-
standing concerns” that the results of many trials “currently remain hidden from public 
view”, which, according to campaigners, “undermines public trust, breaks the ethical pact 
between scientists and those participating in trials and leads to clinical decisions being 
made on the basis of incomplete evidence, potentially leading to poorer outcomes for 
patients”.6 They concluded that:
many of the clinical trials taking place in the UK remain unregistered and 
unpublished and their data continue to be unavailable to both the general 
public and the scientific community. This is unacceptable and we have not 
been impressed by the Government’s efforts to resolve this important issue.7
3. Underlining the need to explore clinical trials transparency as part of our work on 
research integrity, Dr Ben Goldacre, a medical doctor and Director of the Evidence-Based 
Medicine DataLab at the University of Oxford, argued that, five years on from that Report, 
clinical trials transparency remains a significant issue, with non-publication of results 
distorting the evidence base on which important decisions are made:
[Academic] fraud is not the most important issue. The culture of incomplete 
and inaccurate reporting of research has greater impact on patients and 
society […] [Clinical] Trials are large expensive research projects used 
to generate knowledge that is then used, in clinical practice, to make 
1 Science and Technology Committee, Sixth Report of Session 2017–19, Research integrity, HC 350
2 Work on research integrity began during the 2015 Parliament, under the previous Committee. Written evidence 
received by that Committee (i.e. prior to the 2017 General Election) is labelled with ‘RIN’ prefixes; evidence 
received by the current Committee is labelled with ‘RES’ prefixes. All oral evidence for the inquiry took place 
during the 2017 Parliament. For further details see link in footnote 1.
3 Universities UK, The concordat to support research integrity (July 2012), p17
4 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104
5 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104, Chapter 4
6 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104, para 4
7 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104, para 125
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vitally important decisions; and yet trials are commonly left unreported, 
or misreported. This is a waste of money, and distorts the evidence 
underpinning medical practice.8
4. We were told that “around half” of clinical trials currently go unreported (see 
Chapter 2), and that results from clinical trials with positive results were twice as likely 
to be published as others.9 We were also provided with some explicit examples of non-
publication of clinical trials results leading to wasted public expenditure in the UK and 
even patient deaths in other countries. Two examples are set out below:
• Dr Simon Kolstoe, a researcher at the University of Portsmouth and chair of 
two Research Ethics Committees, highlighted the case of the UK Government 
spending £424m to stockpile Tamiflu in response to the H1N1 ‘Swine Flu’ 
epidemic in 2009. He explained that “eight out of the ten trials that were used 
by the company to show the drug was useful in preventing complications such 
as pneumonia had never actually been peer reviewed or published”, which 
meant that governments were “relying on a marketing spiel claiming successful 
trials of this drug rather than being able to consider the actual evidence of 
the drug efficacy for themselves”.10 The House of Commons Public Accounts 
Committee investigated this decision in 2014 and concluded that there was “a 
lack of consensus over how well Tamiflu works, in particular whether it reduces 
complications and mortality,” and that evidence-based policymaking had been 
“hampered because important information about clinical trials is routinely and 
legally withheld from doctors and researchers by manufacturers”.11
• The AllTrials Campaign told us that “a heart drug called Lorcainide was tested 
in a trial in 1980. The results showed that the people who were taking Lorcainide 
were far more likely to die than those not taking it. But those results weren’t 
published until 1993 […] in those thirteen years, doctors continued to give 
patients medicines in the same drug class as Lorcainide and it is estimated that 
100,000 people in the US died as a result.”12
5. On this basis, we took oral evidence from Dr Goldacre, Dr Kolstoe and the AllTrials 
Campaign as part of our research integrity inquiry. We also took evidence from the Health 
Research Authority to explore solutions to the non-publication of clinical trials results. 
Given the significance of this topic as a public health issue, we agreed to produce this 
separate short Report on clinical trials transparency,13 drawing on the evidence we received 
during our work on research integrity and providing an update on our predecessor’s 2013 
Report. We are grateful to everyone who contributed to this aspect of our work.
8 Dr Ben Goldacre (RIN0073) para 0
9 AllTrials campaign (RIN0067)
10 Dr Simon Kolstoe (RIN0022) para s3
11 Public Accounts Committee, Thirty-Fifth Report of Session 2013–14, Access to clinical trial information and the 
stockpiling of Tamiflu, HC 295
12 AllTrials campaign (RIN0067)
13 Science and Technology Committee, Sixth Report of Session 2017–19, Research integrity, HC 350, para 13
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2 The current state of clinical trials 
transparency and related legislation
Definitions
6. The World Health Organization (WHO) defines a clinical trial in broad terms as 
“any research study that prospectively assigns human participants or groups of humans 
to one or more health-related interventions to evaluate the effects on health outcomes”. 
Specifically, the WHO definition includes “drugs, cells and other biological products, 
surgical procedures, radiological procedures, devices, behavioural treatments, process-of-
care changes, preventive care, etc”.14
7. ‘Clinical trials transparency’ is typically discussed in terms of three interconnected 
issues:
• ensuring that details of all clinical trials are recorded in advance in a publicly-
accessible registry (i.e. with legislation and rules designed to tackle ‘non-
registration’);
• ensuring that at least summary results are published within a set timeframe 
following the end of the trial (i.e. with rules to tackle ‘non-reporting’); and
• ensuring that all the results from a trial are reported, rather than just those with 
significant results (i.e. tackling ‘selective reporting’ or ‘mis-reporting’).
Existing legislation, rules and current compliance
8. Clinical trials are heavily regulated, and a wide range of relevant rules and initiatives 
exists to address non-registration, non-reporting and mis-reporting. However, despite 
the existence of these “innumerable regulations, edicts, reports, guidelines and strategy 
documents” relating to clinical trials transparency, Dr Goldacre told us that “none have 
been enforced or implemented, and breaches are not documented”.15 Examples to illustrate 
this are explored below.
Non-registration
9. In 2013, the Health Research Authority (HRA) made it a condition of a trial 
receiving a ‘favourable opinion’ from a research ethics committee that the trial16 must 
be registered—or a deferral for specific reasons requested17—before participants are 
14 World Health Organization, ‘Health topics: clinical trials’, accessed 31 August 2018
15 Dr Ben Goldacre (RIN0073) para 3
16 The requirement encompasses: clinical trials of an investigational medicinal product; clinical investigations or 
other study of a medical device; combined trial of an investigational medicinal product and an investigational 
medical device; and other clinical trials to study a novel intervention or randomised clinical trial to compare 
interventions in clinical practice.
17 Reasons for deferral could include commercial sensitivity. There is an expectation that the trial will be registered 
when the reason for the deferral is no longer valid or immediately should the trial be terminated early for safety 
reasons.
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recruited.18 The HRA subsequently conducted several audits of registration, with follow-
up contact with lead investigators where non-compliance was found. These demonstrated 
that registration was still not universal, even among trials that had received a favourable 
opinion, and that some who fell short on their compliance ignored contact from the HRA. 
The HRA’s 2017 audit revealed that 32% of 599 studies that received a ‘favourable opinion’ 
(and no agreed deferral) could not be found on a publicly accessible registry.19 Moreover, 
of the 194 lead researchers contacted regarding non-registration, 73 failed to respond to 
the HRA within a week to provide an explanation or take steps to register.20 The HRA 
concluded that “awareness that the requirement to register a clinical trial as a condition of 
favourable opinion was variable. Many responders did not know how or where to register 
their study and what was an acceptable register for their study type”.21 Four of the non-
respondents related to phase I drug trials;22 we were told that the current status of these 
trials had been explored further after the audit: one was already on the US public register, 
clinicaltrials.gov, two were taking action to register publicly, prompted by the HRA’s 
follow-up, and the other trial did not start so it did not need public registration.23
Non-reporting
10. Since July 2014 the European Commission has required all trials on the EU Clinical 
Trials Register (i.e. trials of medicinal products) to post results to the registry within 12 
months of completion, with a final compliance date of 21 December 2016.24 The first 
analysis of compliance with this requirement was undertaken by Dr Goldacre and his 
team at the Evidence-Based Medicine DataLab this year. That study identified 7,274 trials 
where it could be verified that results were now due. Of these, just 49.5% had reported 
results.25 This further reinforces the assessment made by the AllTrials campaign made 
that “around half” of trials go unreported, drawing on a range of research on this topic.26 
The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for 
ensuring that sponsors provide results for drug trials (i.e. a subset of all clinical trials) in 
the UK that are registered in the European Clinical Trials Register. The HRA told us that 
it would “seek to work with the MHRA to understand better the situation regarding the 
trials they regulate”.27
18 Health Research Authority, Clinical Trial Registration: Audit of compliance for period 1 January 2016 to 30 
June 2016 (August 2017), p1. The registration condition applies throughout the UK as a result of the HRA’s 
coordination with the Devolved Administrations, as per s111(4) of the Care Act 2014.
19 Health Research Authority, Clinical Trial Registration: Audit of compliance for period 1 January 2016 to 30 June 
2016 (August 2017), p4
20 Health Research Authority, Clinical Trial Registration: Audit of compliance for period 1 January 2016 to 30 June 
2016 (August 2017), p8. The audit report notes that “The response rate from investigators / sponsors when 
contacted regarding study registration was reasonably good, given the short response window (one week from 
when the email was sent and no reminder emails were issued)”.
21 Health Research Authority, Clinical Trial Registration: Audit of compliance for period 1 January 2016 to 30 June 
2016 (August 2017), p11
22 ‘Phase I’ refers to a therapy being given to a group of people for the first time.
23 Health Research Authority (RES0047)
24 European Medicines Agency, ‘Posting of clinical trial summary results in European Clinical Trials Database 
(EudraCT) to become mandatory for sponsors as of 21 July 2014’, accessed 24 August 2018
25 Goldacre, B. “Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and 
web resource”, The BMJ, 2018; 362:k3218
26 AllTrials campaign (RIN0067)
27 Health Research Authority (RES0047)
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11. Reporting requirements are also specified by UK funders. In October 2016 the 
Medical Research Council (MRC) clarified its policy on clinical trials reporting, including 
a requirement for award holders to ensure that findings are publicly available within 12 
months of completion of the trial.28 This appears to have been successful as compliance 
rates are relatively high for MRC-funded trials. In 2017, the MRC examined reporting 
rates for trials funded between 2011 and 2016, finding that 33 out of 40 trials (~82%) 
that had been completed for at least a year had reported in at least one publication.29 The 
Government referred several times during our inquiry to the relatively high compliance 
rate for MRC-funded trials.30 However, the MRC’s role in clinical trials is relatively small; 
it funds around 120 clinical trials each year,31 representing less than 3% of the 4,568 
studies reviewed by the HRA in 2017/18.32
12. The current EU Clinical Trials Directive33 (incorporated into UK law via the 2004 
Medicines for Human Use (Clinical Trials) Regulations34) will soon be superseded by a new 
EU Clinical Trials Regulation.35 This Regulation includes new transparency requirements 
regarding publication of trial results and requires Member States to lay down rules on 
penalties for non-compliance.36 Although the new Regulation entered into force on 16 
June 2014, the point at which it becomes applicable to the Member States is contingent on 
the completion of a new EU clinical trials portal and database; the Regulation becomes 
applicable six months after the European Commission publishes confirmation that the 
portal and database are fully functional. This is expected to happen in 2019, after the 
UK leaves the EU, and so the Regulation will not be incorporated into UK law by the EU 
(Withdrawal) Act. The Government has stated that it will “align where possible with the 
[new Regulation] without delay when it does come into force in the EU, subject to usual 
parliamentary approvals”.37 What this commitment to “align” with the Regulation will 
mean in the context of forthcoming clinical trials transparency requirements (and any 
corresponding penalties for non-reporting) is currently unclear.
Mis-reporting
13. A multi-journal initiative exists to ensure that the full results from trials are reported. 
The Consolidated Standards of Reporting Trials (CONSORT) statement, first published 
in 1996 and updated in 2010, sets out “a standard way for authors to prepare reports of 
trial findings, facilitating their complete and transparent reporting, and aiding their 
critical appraisal and interpretation”.38 Its checklist requires all outcomes to be defined 
and identified, and results to be reported for each outcome.
28 Medical Research Council (RES0041) para 1.1
29 MRC, MRC Clinical Trials Transparency Review Final Report (November 2017), (November 2017), para 14
30 Q598 [Sir Mark Walport], Department for Business, Energy and Industrial Strategy (RES0057),
31 MRC, MRC Clinical Trials Transparency Review Final Report (November 2017), (November 2017), para 17
32 Health Research Authority, Health Research Authority Annual Report and Accounts 2017/18, HC 1284
33 Council Directive 2001/20/EC
34 The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)
35 Council Regulation (EC) No. 536/2014
36 For further details see ‘Clinical trial regulation’, European Medicines Agency, accessed 24 August 2018, and 
Article 94 of Council Regulation (EC) No. 536/2014.
37 ‘Guidance: How medicines, medicinal devices and clinical trials would be regulated there’s no Brexit deal’, gov.
uk, 23 August 2018
38 http://www.consort-statement.org/
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14. Despite “over 500 individually named academic journals”39 having formally endorsed 
the CONSORT guidelines for trial reporting, mis-reporting remains an issue. A study of 
the work of Hampshire A research ethics committee by Dr Kolstoe found that 57% of 
publications associated with trials approved by the committee showed “inconsistencies 
with the outcomes originally declared in the ethics application”.40 Similarly the Medical 
Research Council told us that while reporting rates for the trials it funds were high, in its 
most recent audit of corresponding publications “only half of these appeared to include 
the main trial results”.41
15. A range of UK and EU rules and guidelines are in force to improve clinical trials 
transparency, in terms of tackling non-registration, non-reporting and mis-reporting. 
Despite these rules, around half of clinical trials are left unreported, clinical trial 
registration is not yet universal in the UK and reported outcomes do not always align 
with the original study proposal. Further action is needed to improve reporting and 
registration of clinical trials, as we set out in this Report. The Government should not 
rely on the higher reporting rates for trials funded by the Medical Research Council to 
suggest that the problem is being addressed, as these represent a small proportion of 
the total number of clinical trials undertaken in the UK.
16. The Government should explicitly commit to introducing the clinical trials 
transparency requirements in the EU Clinical Trials Regulation that are expected to be 
applied in the EU shortly after Brexit.
Compliance rates by sponsor
17. Dr Goldacre’s recent work has also revealed that compliance with reporting 
requirements varied by sponsor—i.e. the “individual, company, institution, organisation 
or group of organisations that takes on responsibility for initiation, management and 
financing (or arranging the financing) of the research”.42 Trials with a commercial sponsor 
were substantially more likely to post results than those with a non-commercial sponsor 
(68.1% vs 11.0%). In particular, “compliance among pharmaceutical companies has been 
good; while universities have performed poorly”.43 However, the study found considerable 
variation between universities. The University of Dundee, for instance, has a compliance 
rate of 82%, whereas the equivalent figure for the University of Nottingham is 5.9%.44
18. Dr Patrick Vallance, the Government’s Chief Scientific Adviser, told us that his 
message to universities with low trial reporting rates was to “sort it out”.45 The Science 
Minister, Sam Gyimah MP, agreed with this message.46 The work being undertaken by 
Universities UK to review the Concordat to Support Research Integrity in response to our 
earlier Report on this subject represents an important opportunity to press for progress 
on this issue.47
39 Dr Ben Goldacre (RIN0073), para 1.3
40 Dr Simon Kolstoe (RIN0022)
41 Medical Research Council (RES0041) para 3.3
42 Health Research Authority, ‘Roles and responsibilities’, accessed 30 August 2018
43 Goldacre, B. “Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and 
web resource”, The BMJ, 2018; 362:k3218
44 According to data published at https://eu.trialstracker.net as at 22 October 2018
45 Q661
46 Q663
47 See Science and Technology Committee, Sixth Report of Session 2017–19, Research integrity, HC 350, para 43
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19. Compliance with transparency rules varies by sponsor—while pharmaceutical 
companies have good rates of reporting within a reasonable timeframe, the picture 
is much more mixed for universities. We welcome the Science Minister and the 
Government Chief Scientist’s call for universities to deal with this problem and expect 
universities to take heed. Every university should aim for 100% compliance. We 
recommend that the updated and strengthened Concordat to Support Research Integrity 
being developed by Universities UK should include requirements on universities to 
ensure that all trials are reported, and that efforts are made to share best practice in 
achieving compliance with reporting rules within the university sector.
20. The ‘EU Trials Tracker’ website set up by Dr Goldacre and colleagues at the Evidence-
Based Medicine Data Lab also reveals that Public Health England has three overdue trials 
dating from 2010–2016 relating to meningitis vaccines.48 Meanwhile, many NHS Trusts 
have high numbers of unreported clinical trials according to the site: the Manchester 
University NHS Foundation Trust has 13 overdue trials, NHS Greater Glasgow and Clyde 
has 12 that are due to have reported, and both Newcastle upon Tyne Hospitals NHS 
Foundation Trust and Hull and East Yorkshire Hospitals NHS Trust have 11 outstanding 
trials.49
21. It is particularly disappointing that trusted bodies such as Public Health England 
and a range of NHS Foundation Trusts are also failing to report results from clinical 
trials. Public trust in medicine could easily be eroded by failures in clinical trials 
transparency from such important parts of the health system. Public Health England 
should write to us with an explanation and the steps it will take to correct this.
48 See https://eu.trialstracker.net/sponsor/public-health-england accessed 22 October 2018.
49 Data taken from https://eu.trialstracker.net accessed 22 October 2018.
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3 Improving clinical trials transparency
Developments since 2013 and the need for high-level political 
leadership
22. Since our predecessor’s Report, clinical trials transparency has been discussed “at 
the highest levels”,50 with a number of international and intergovernmental organisations 
releasing statements on this issue:
• In April 2015, the World Health Organization published a statement on the 
public disclosure of clinical trial results. The WHO statement defined reporting 
timeframes, called for results-reporting of older but still unpublished trials, and 
outlined steps to improve linkages between clinical trial registry entries and 
their published results.51
• In September 2016, the UN Secretary-General’s High-Level Panel on Access 
to Medicines placed the responsibility for making progress on this issue with 
national governments. It recommended that “Governments should require that 
the unidentified data on all completed and discontinued clinical trials be made 
publicly available in an easily searchable public register established and operated 
by existing mechanisms such as the WHO Clinical Trials Registry Platform, 
clinicaltrials.gov or in peer reviewed publications, regardless of whether their 
results are positive, negative, neutral or inconclusive”.52
• In May 2017 the WHO produced a joint statement on public disclosure of results 
from clinical trials, with 21 signatories committing to “develop and implement 
a policy with mandated timeframes for prospective registration and public 
disclosure of the results of clinical trials” that they fund, co-fund, sponsor or 
support within 12 months of completion. Moreover, the signatories committed to 
“monitor registration and endorse the development of systems to monitor results 
reporting on an ongoing basis”, with outputs from the monitoring process being 
made publicly available. UK signatories include the Medical Research Council, 
the Department for International Development and the National Institute for 
Health Research.53
23. The issue was also previously discussed at the highest level within the UK. Following 
the Ebola epidemic, in 2015 the then Prime Minister David Cameron told a G7 summit 
that:
The UK will be the first country in the world to require clinical trials and 
disease control operations to be fully transparent. From now on any UK-
funded research, data or operation will be made openly available and the 
50 Q319 [Síle Lane]
51 World Health Organization, ‘WHO statement on public disclosure of clinical trials results’, accessed 23 August 
2018
52 United Nations Secretary-General’s High-Level Panel on Access to Medicines, Promoting innovation and access 
to technologies (September 2016), para 4.3.5
53 World Health Organization, ‘Joint statement on public disclosure of results from clinical trials’, accessed 23 
August 2018
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UK will look to develop an international agreement—via the G7—that 
would see the publication of results of all clinical trials of vaccines for 
relevant diseases.54
However, the focus for this commitment was specifically trials relating to potential global 
pandemics, and there does not appear to be any tangible progress even on this more limited 
aspect. In particular, Dr Goldacre told us that “there are many trials of both treatments 
and vaccines for Ebola that have completed but not reported results, including I believe 
some from the UK”.55
24. We were told that further political attention in the UK was required to make progress 
on this issue. TranspariMED argued that “so far, the systematic distortion of evidence 
generated by clinical trials has been largely framed as a technical issue, rather than as a 
political issue”.56 Dr Goldacre warned that the public were “increasingly aware that serious 
problems [with transparency] have been left unaddressed: that trial results are routinely 
withheld, that there has been little serious effective effort to fix the issue over decades, that 
the biggest players in the ecosystem of scientific research are not taking adequate action”. 
He argued that an ongoing failure to address these problems “[laid] fertile ground for 
quacks, anti-vaccination conspiracy theorists, and climate change denialists”.57
25. Our predecessor Committee concluded in 2013 that it had “not been impressed” 
by the Government’s efforts to resolve the problem of un-registered, non-reported and 
mis-reported clinical trials. We believe that while there have been some improvements 
there is still much more to be done.
26. We welcome the recent statements and recommendations from the WHO and 
the UN on clinical trials transparency aimed at improving registration and reporting 
rates. The Ebola epidemic prompted political attention in the UK to the risks to 
public health of non-publication of clinical trial results, with the then Prime Minister 
David Cameron making commitments to clinical trials transparency in 2015. Since 
then, progress has slowed in the UK at a political level. Clinical trials transparency 
is as much a question of political will as it is a technical issue. We recommend that 
the Government explicitly re-commit to tackling clinical trials transparency, perhaps 
through a focused ministerial speech on this issue. This should set a clear time limit for 
institutions to fully comply with clinical trials transparency requirements and make 
clear what the consequences will be of failing to meet that deadline.
Improving registration and reporting rates through auditing
27. An approach to improving clinical trials transparency emphasised by our witnesses 
was publishing better information on which clinical trials have reported and which have 
not. Dr Goldacre explained that “we need to know which researchers are the best and 
the worst, and which institutions are the best and the worst, because that is information 
we can act on. Assuming good faith, I hope that the institutions that have fallen behind 
would want to learn from those doing well at reporting their clinical trials”.58
54 Gov.uk, ‘Prime Minister calls for ‘wake-up to the threat from disease outbreak’’, 7 June 2015
55 Q341
56 TranspariMED (RIN0018) para 7
57 Dr Ben Goldacre (RIN0073) para 2
58 Q323
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28. Recent attempts to provide such information are described in Chapter 2. Surprisingly, 
information on whether an individual trial has published results is not readily available 
online without secondary analysis. Such work has been undertaken by Dr Goldacre and 
others to match information in clinical trial registries with publications records, with 
information on sponsor compliance rates published online.59 Despite the scope for using 
audits to drive improvements in compliance rates, Dr Goldacre found that his attempts 
to put trial-by-trial information in the public domain were seen as subversive. He told us 
that:
When you finish an audit showing which institutions in the UK are best 
and worst at reporting their clinical trial results at all, and which are best at 
reporting their clinical trial results on time, people sometimes respond as if 
you are doing something that somehow is transgressive or confrontational, 
which shows how far we have to go. It would be a very straightforward 
thing to fix. This Committee could write to the Health Research Authority 
and say, “We want you to audit every trial that you approve; we want you 
to publish line by line; we want you to identify the individual trials and 
trialists who have not published their results”.60
29. Our witnesses argued that an appropriate official provider of trial-by-trial 
information on registration and reporting compliance was the Health Research Authority 
(HRA), drawing on its oversight and coordination of research ethics committees (RECs) 
in the UK.61 Under both the EU Clinical Trials Directive 2001 and UK governance 
arrangements, in order to obtain clinical trial authorisation, all UK trials must first be 
evaluated and approved by an accredited REC. RECs therefore hold large amounts of 
information on proposed trials, albeit with some aspects being confidential for commercial 
reasons.62 Indeed, our predecessor Committee recommended in 2013 that “Research 
Ethics Committees should have a role in considering and monitoring compliance with 
transparency policies”.63
30. We asked Professor Jonathan Montgomery, the non-executive Chair of the HRA, 
whether there were any barriers to the HRA publishing all the information it holds on 
which clinical trials have reported and which have not. He told us that:
We hold data that comes through in relation to projects, some of which 
is commercially sensitive, and within our processing systems we need to 
respect the basis on which people have given that to us. […] However, going 
forward in relation to whether trials have resulted in publication, I see no 
reason why we cannot match publicly available data.64
59 See https://eu.trialstracker.net
60 Q318
61 Responsibility for regulation of most health and social care research in Wales, Scotland and Northern Ireland 
remains with each Devolved Administration, since health and social care are themselves devolved matters. 
However, the HRA performs various functions relating to research ethics committees on behalf of the Devolved 
Administrations by arrangement, as per the Care Act 2014 Schedule 7 paragraph 15.
62 Dr Simon Kolstoe (RIN0022) para s5
63 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104, para 110
64 Q498
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He also told us that he was “not in favour of naming and shaming” organisations with 
poor compliance records but would nevertheless be “very keen to make transparent who 
has and has not published” as a prompt to encourage publication.65
31. Non-compliance with reporting rules is not currently documented by public 
bodies on a trial-by-trial basis. Official publication of such information would expose 
where there are weaknesses in compliance and where best practice within the sector 
could be found and shared. We welcome recent efforts by Dr Goldacre and the AllTrials 
campaign to make information on reporting rates available online. However, it should 
not be left to researchers and campaigners to collate and publish this information 
themselves. We turn to the issue of who should produce this information later in this 
chapter.
Models for auditing compliance
32. We heard about a range of possible models for auditing compliance. A joint submission 
from STOPAIDS, Healthwatch UK, Universities Allied for Essential Medicines UK and 
TranspariMED described various options for questions that an audit could seek to address, 
and the relative difficulty of conducting such an exercise.
Table 1: Types of audit
Audit question Audit methodology
Was this clinical trial prospectively 
registered?
Easy to audit. There are only 16 WHO-
recognised primary registries that the HRA 
needs to search for each trial.
Were the summary results of this clinical 
trial published on all the registries where 
it is registered within 12 months of study 
completion?
Very easy to audit. The HRA can quickly 
check the already identified registry entries 
for trial results.
Has this clinical trial published results in 
an academic journal following global best 
practices [including referencing the unique 
ID number of the trial issued by the registry 
in the abstract of the corresponding 
journal article]?
Very easy to audit. The HRA can quickly 
search journal databases for the trial 
number.
Are the registration and results data for 
this trial consistent across different registry 
entries?
For trials registered in more than one 
registry the HRA can check whether key 
trial data is consistent across different 
registries. This requires no specialist skills, 
but does require manual comparison.
Has this trial ever reported its results 
anywhere?
Time intensive to audit. The HRA would 
need to follow a lengthy search protocol 
for every trial. No specialist skills required.
Has this trial accurately reported its results? Time intensive and difficult to audit. The 
HRA would need to conduct a trial-by-trial 
analysis. This requires specialist skills.
Source: STOPAIDS et al (RES0036)
65 Q504
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33. We explored some of these options and the relative costs with our witnesses. Dr 
Goldacre argued that the HRA could use automated tools which searched databases for 
publications to answer the question of whether a trial had published results in an academic 
journal. However, Dr Kolstoe argued that this approach would “solve less than half of the 
problem”, since “determining whether results have been posted does not address whether 
they appropriately represent the study that was actually conducted”.66 He argued that, 
since the HRA had access to all of the confidential research protocols, it could also support 
the research ethics committees to compare outcomes reported in publications with the 
objectives specified in the original protocols to check for mis-reporting or selective non-
reporting.
34. Dr Kolstoe told us that while it could be “relatively cheap and easy” to audit non-
publication using automated software and data held by the HRA, in order to address 
“outcome reporting bias” a manual comparison would need to be made of the final study 
reports against the original proposal.67 He had conducted such an audit for the Hampshire 
A Research Ethics Committee to demonstrate that it was possible to do this. He argued 
that those with access to REC records were “in a particularly powerful position to detect 
publication and reporting bias in contrast to similar attempts conducted by research 
funders or systematic review organisations who do not have immediate access to such a 
wide range of otherwise confidential protocols”.68
35. Dr Kolstoe noted that “extra resources would be needed if individual RECs or those 
managing them were to take on this role more comprehensively”.69 The HRA claimed that 
the total cost of undertaking this work would be £2.4m, but did not provide a basis for this 
estimate.70 They warned that “without a significant increase in our funding, any active 
monitoring of all research projects approved by the HRA using this methodology would 
we believe have a detrimental impact on other areas of our services, such as approval 
timelines”.71 Jonathan Montgomery from the HRA told us that he thought it would be 
unlikely to ever secure such additional funding, and that it would not be “a sufficient 
priority against all the other things we are doing if we did have that money to deal with 
it”.72 He contrasted this cost with “about £250,000” for an IT-based solution, albeit one 
which would not address the question of whether the matched publication addressed the 
full aims of the trial or was a partial report.73
36. We recommend that the Health Research Authority (HRA) should be provided 
with funding to establish a national audit programme of clinical trials transparency, 
including the publication of a single official list of which UK trials have published 
results and those which are due to but have not. In the first instance this should focus 
on providing information on whether any results have been published in an academic 
journal following global best practice, building on the automated methods already 
developed by others. We recognise that there are other dissemination routes for clinical 
trials results beyond academic journals that automated methods might not capture. 
66 Dr Simon Kolstoe (RES0030)
67 Dr Simon Kolstoe (RES0030)
68 Dr Simon Kolstoe (RIN0022)
69 Dr Simon Kolstoe (RIN0022)
70 Health Research Authority (RES0040) para 12
71 Health Research Authority (RES0040) para 12
72 Q517
73 Qq517–519
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Where alternative means have been used to publish information the HRA can use this 
process to prompt lead investigators to provide details of where the results have been 
posted so that the entry for that trial can be corrected as necessary.
37. We are disappointed that the HRA does not believe it can secure funding for a more 
comprehensive form of audit and does not see this as a priority. Even if the cost of fully 
assessing reported trial outcomes against the original specification in the application 
for ethical approval amounts to £2.4m per year, as the HRA suggested in evidence to 
us, this is a small price to pay compared with the sums of money involved in policy 
decisions that draw on clinical trials evidence, such as the £424m the Government 
spent on stockpiling Tamiflu without full access to evidence on its effectiveness. We 
recommend that the HRA undertake further work to determine an accurate figure for 
the cost of such an audit and prepare a funding proposal for the Government to consider. 
The cost should be weighed against the potential public savings made by tackling mis-
reporting, in terms of reduced ‘research wastage’ and the scope for better procurement 
decisions. If this model is pursued, then the results should be published trial-by-trial 
rather than simply at the summary level.
38. The Government should direct the HRA to publish information on trials that have 
received ethical approval but are not registered in a publicly-accessible register, on a 
trial-by-trial basis.
Sanctions for non-compliance
39. Our predecessor Committee in 2013 recommended that the HRA should introduce 
“penalties for non-compliance” with registration and reporting rules.74 We asked Professor 
Montgomery, non-executive Chair of the HRA, whether the HRA had the statutory power 
to impose meaningful sanctions for non-compliance. Professor Montgomery told us that 
“we do not have sanctions as part of the HRA, other than refusing permissions […] we do 
not employ the researchers so our only real powers are to withhold [ethical] permissions 
or refer to those who do have those powers”.75
40. Naturally the ethical permission for a trial cannot be withheld after the research 
has taken place as a response to non-reporting. However, the REWARD Alliance, an 
international alliance focused on reducing wastage in research, suggested to us that 
research ethics committees could refuse to approve proposals for further research unless 
the sponsor or researcher can show that their previous research had been reported.76 Dr 
Goldacre agreed that “ethics committees should not allow researchers to have access to 
patients unless they can show that they have published the results of all the trials they 
have previously conducted”.77 We asked Professor Montgomery whether this would be 
possible:
74 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104, para 110
75 Q515
76 REWARD Alliance (RIN0013) para 8.3
77 Qq316–317
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I think that would be tricky. […] We took to our research ethics committee 
members the question of whether we should make it a condition of a new 
application that results had been published within 12 months of completion 
of the previous ones. There was quite strong resistance to that. There was 
a group that simply told us it did not think it should happen; a group that 
thought it would not be possible to deliver on it; and a group that thought 
it was too ambiguous.78
Instead he argued that others could make decisions based on non-compliance information 
if it were made available, as we recommend (at paragraph 36):
I am not convinced that the ethics committee is the right bit of the system 
to do that. […] I would expect sponsors to be interested in whether their 
money had been well spent previously and led to the reported outcomes. I 
would expect the hosts of research to want to know it was worth hosting 
that research, so we should be providing them with the opportunity to ask 
whether they trust a particular research group or sponsor to deal with it.79
41. The HRA appears to be reluctant to enforce its rules, or to make previous compliance 
with transparency legislation a pre-requisite for ethical approval of future trials. As a 
result, there are currently no sanctions imposed on sponsors or investigators who fail 
to comply with HRA rules, or even on those who fail to respond to the HRA when 
their non-compliance is queried. Echoing our predecessor Committee’s conclusions 
from 2013, we recommend that the HRA introduce a system of sanctions to drive 
improvements in clinical trials transparency, such as withdrawing favourable ethical 
opinion or preventing further trials from taking place. The Government should consult 
specifically on whether to provide the HRA with the statutory power to fine sponsors for 
non-compliance.
Allocating responsibility for driving improvement
42. Our predecessor Committee recommended that the Government make the promotion 
of research transparency a statutory objective of the Health Research Authority.80 As a 
result, in 2013 the Government tabled an amendment to the Care Bill at Report stage 
which made it explicit that the HRA’s main objective of “protecting and promoting the 
interests of participants, potential participants and the public by facilitating the conduct 
of safe, ethical research” included “promoting transparency in research”.81 The Bill which 
became the Care Act 2014 clarified that ‘transparency’ included the registration of research 
and the publication and dissemination of research findings and conclusions.82 Our Chair 
was the lead Minister for the Bill at the time.
78 Qq511–512
79 Q520
80 Science and Technology Committee, Third Report of Session 2013–14, Clinical trials, HC 104, para 109
81 Department of Health, Government response to the Science and Technology Committee inquiry into clinical 
trials, Cm 8743, November 2013, para 27
82 Care Act 2014, section 110 (7)
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43. The HRA’s 2017/18 annual report listed “being a champion for transparency in 
research” as part of its strategic objectives, and noted that a “key risk” for the HRA related 
to “expectations around transparency and the HRA’s ability to deliver within its current 
remit”.83 Nevertheless, the HRA told us that “as far as our regulatory remit is concerned, 
we feel that we have sufficient scope to act within the existing legislation”.84
44. The annual report also stated that further work to consider transparency was 
underway, “with closer links with key partners being made to support the delivery of the 
transparency agenda together with refreshed key performance indicators for 2018/19”.85 
There are currently no measurable performance indicators relating to transparency in the 
report. The two achievements listed for the year in its “performance scorecard” are that 
the HRA had “performed an audit of clinical trial registration and published the findings 
report on [the HRA’s] website” (as it has done for several years, at a summary level), and 
“compiled a list of accepted clinical trial registers with [its] Transparency Forum and 
published this list on our website”.86
45. The Health Research Authority has been explicitly responsible for “promoting 
research transparency” as part of its statutory objectives since 2014, but this does not 
appear to have brought about significant change in this area over the last four years. 
We recommend that the Government ask the HRA to publish, by December 2019, a 
detailed strategy for achieving full clinical trials transparency, with a clear deadline 
and milestones for achieving this. We also recommend that the Government write to the 
HRA to clarify that it should interpret the Care Act 2014 to mean that it is responsible 
for driving improvements in clinical trials transparency—as opposed to ‘promoting’ 
transparency as a virtue. The performance of the HRA should then be explicitly 
measured on this basis through its annual report, including through specific measurable 
performance indicators. If further financial resource for the HRA is required to tackle 
clinical trials transparency then the Government should consider favourably such 
requests.
46. We recommend that the Government consult further with the HRA on whether it is 
capable of delivering the improvements to clinical trials transparency needed within its 
current remit. If necessary its remit should be extended through introducing legislation 
which amends the provisions of the Care Act 2014.
83 Health Research Authority, Health Research Authority Annual Report and Accounts 2017/18, HC 1284
84 Health Research Authority (RES0040) para 13
85 Health Research Authority, Health Research Authority Annual Report and Accounts 2017/18, HC 1284
86 Health Research Authority, Health Research Authority Annual Report and Accounts 2017/18, HC 1284
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Conclusions and recommendations
The current state of clinical trials transparency and related legislation
1. A range of UK and EU rules and guidelines are in force to improve clinical trials 
transparency, in terms of tackling non-registration, non-reporting and mis-
reporting. Despite these rules, around half of clinical trials are left unreported, 
clinical trial registration is not yet universal in the UK and reported outcomes 
do not always align with the original study proposal. Further action is needed to 
improve reporting and registration of clinical trials, as we set out in this Report. The 
Government should not rely on the higher reporting rates for trials funded by the 
Medical Research Council to suggest that the problem is being addressed, as these 
represent a small proportion of the total number of clinical trials undertaken in the 
UK. (Paragraph 15)
2. The Government should explicitly commit to introducing the clinical trials transparency 
requirements in the EU Clinical Trials Regulation that are expected to be applied in 
the EU shortly after Brexit. (Paragraph 16)
3. Compliance with transparency rules varies by sponsor—while pharmaceutical 
companies have good rates of reporting within a reasonable timeframe, the picture 
is much more mixed for universities. We welcome the Science Minister and the 
Government Chief Scientist’s call for universities to deal with this problem and 
expect universities to take heed. Every university should aim for 100% compliance. 
We recommend that the updated and strengthened Concordat to Support Research 
Integrity being developed by Universities UK should include requirements on 
universities to ensure that all trials are reported, and that efforts are made to share 
best practice in achieving compliance with reporting rules within the university sector. 
(Paragraph 19)
4. It is particularly disappointing that trusted bodies such as Public Health England 
and a range of NHS Foundation Trusts are also failing to report results from 
clinical trials. Public trust in medicine could easily be eroded by failures in clinical 
trials transparency from such important parts of the health system. Public Health 
England should write to us with an explanation and the steps it will take to correct 
this. Public Health England should write to us with an explanation and the steps it 
will take to correct this (Paragraph 21)
Improving clinical trials transparency
5. Our predecessor Committee concluded in 2013 that it had “not been impressed” 
by the Government’s efforts to resolve the problem of un-registered, non-reported 
and mis-reported clinical trials. We believe that while there have been some 
improvements there is still much more to be done. (Paragraph 25)
6. We welcome the recent statements and recommendations from the WHO and the 
UN on clinical trials transparency aimed at improving registration and reporting 
rates. The Ebola epidemic prompted political attention in the UK to the risks to 
public health of non-publication of clinical trial results, with the then Prime Minister 
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David Cameron making commitments to clinical trials transparency in 2015. Since 
then, progress has slowed in the UK at a political level. Clinical trials transparency 
is as much a question of political will as it is a technical issue. We recommend that 
the Government explicitly re-commit to tackling clinical trials transparency, perhaps 
through a focused ministerial speech on this issue. This should set a clear time limit for 
institutions to fully comply with clinical trials transparency requirements and make 
clear what the consequences will be of failing to meet that deadline. (Paragraph 26)
7. Non-compliance with reporting rules is not currently documented by public bodies 
on a trial-by-trial basis. Official publication of such information would expose 
where there are weaknesses in compliance and where best practice within the 
sector could be found and shared. We welcome recent efforts by Dr Goldacre and 
the AllTrials campaign to make information on reporting rates available online. 
However, it should not be left to researchers and campaigners to collate and publish 
this information themselves. We turn to the issue of who should produce this 
information later in this chapter. (Paragraph 31)
8. We recommend that the Health Research Authority (HRA) should be provided with 
funding to establish a national audit programme of clinical trials transparency, 
including the publication of a single official list of which UK trials have published 
results and those which are due to but have not. In the first instance this should focus 
on providing information on whether any results have been published in an academic 
journal following global best practice, building on the automated methods already 
developed by others. We recognise that there are other dissemination routes for clinical 
trials results beyond academic journals that automated methods might not capture. 
Where alternative means have been used to publish information the HRA can use this 
process to prompt lead investigators to provide details of where the results have been 
posted so that the entry for that trial can be corrected as necessary. (Paragraph 36)
9. We are disappointed that the HRA does not believe it can secure funding for a more 
comprehensive form of audit and does not see this as a priority. Even if the cost 
of fully assessing reported trial outcomes against the original specification in the 
application for ethical approval amounts to £2.4m per year, as the HRA suggested 
in evidence to us, this is a small price to pay compared with the sums of money 
involved in policy decisions that draw on clinical trials evidence, such as the £424m 
the Government spent on stockpiling Tamiflu without full access to evidence on 
its effectiveness. We recommend that the HRA undertake further work to determine 
an accurate figure for the cost of such an audit and prepare a funding proposal for 
the Government to consider. The cost should be weighed against the potential public 
savings made by tackling mis-reporting, in terms of reduced ‘research wastage’ and the 
scope for better procurement decisions. If this model is pursued, then the results should 
be published trial-by-trial rather than simply at the summary level. (Paragraph 37)
10. The Government should direct the HRA to publish information on trials that have 
received ethical approval but are not registered in a publicly-accessible register, on a 
trial-by-trial basis. (Paragraph 38)
11. The HRA appears to be reluctant to enforce its rules, or to make previous compliance 
with transparency legislation a pre-requisite for ethical approval of future trials. 
As a result, there are currently no sanctions imposed on sponsors or investigators 
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who fail to comply with HRA rules, or even on those who fail to respond to the 
HRA when their non-compliance is queried. Echoing our predecessor Committee’s 
conclusions from 2013, we recommend that the HRA introduce a system of sanctions 
to drive improvements in clinical trials transparency, such as withdrawing favourable 
ethical opinion or preventing further trials from taking place. The Government should 
consult specifically on whether to provide the HRA with the statutory power to fine 
sponsors for non-compliance. (Paragraph 41)
12. The Health Research Authority has been explicitly responsible for “promoting 
research transparency” as part of its statutory objectives since 2014, but this does 
not appear to have brought about significant change in this area over the last four 
years. We recommend that the Government ask the HRA to publish, by December 
2019, a detailed strategy for achieving full clinical trials transparency, with a clear 
deadline and milestones for achieving this. We also recommend that the Government 
write to the HRA to clarify that it should interpret the Care Act 2014 to mean that it 
is responsible for driving improvements in clinical trials transparency—as opposed 
to ‘promoting’ transparency as a virtue. The performance of the HRA should then 
be explicitly measured on this basis through its annual report, including through 
specific measurable performance indicators. If further financial resource for the HRA 
is required to tackle clinical trials transparency then the Government should consider 
favourably such requests. (Paragraph 45)
13. We recommend that the Government consult further with the HRA on whether it is 
capable of delivering the improvements to clinical trials transparency needed within 
its current remit. If necessary its remit should be extended through introducing 
legislation which amends the provisions of the Care Act 2014. (Paragraph 46)
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Formal minutes
Tuesday 23 October 2018
Members present:
Stephen Metcalfe, in the Chair
Vicky Ford
Bill Grant
Darren Jones
Carol Monaghan
Damien Moore
Graham Stringer
Draft Report (Research integrity: clinical trials transparency), proposed by the Chair, 
brought up and read.
Ordered, That the draft Report be read a second time, paragraph by paragraph.
Paragraphs 1 to 46 read and agreed to.
Summary agreed to.
Resolved, That the Report be the Tenth Report of the Committee to the House.
Ordered, That the Chair make the Report to the House.
Ordered, That embargoed copies of the Report be made available, in accordance with the 
provisions of Standing Order No. 134.
[Adjourned till Tuesday 30 October at 9.00 am
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The following witnesses gave evidence. Transcripts can be viewed on the inquiry publications 
page of the Committee’s website.
Tuesday 24 October 2017 Question number
Professor Dorothy Bishop, Professor of Developmental Neuropsychology, 
University of Oxford; Dr Arnaud Vaganay, Director, Meta-Lab; and Professor 
Dame Ottoline Leyser FRS, former Chair, Steering Group on the Culture of 
Scientific Research, Nuffield Council on Bioethics Q1–47
Dr Elizabeth Wager, Publications Consultant, Sideview, and Honorary Co-
ordinator, the REWARD Alliance; Professor Sir Ian Diamond, Research Policy 
Network, Universities UK; Professor Ian Walmsley, Pro Vice Chancellor 
for Research Working Group, Russell Group; and Dr Peter Wilmshurst, 
Consultant Cardiologist, Royal Stoke University Hospital Q48–114
Tuesday 21 November 2107
Professor David Hand, Royal Statistical Society; Dr Damian Pattinson, Vice 
President of Publishing Innovation, Research Square; and Wendy Appleby, 
Registrar and Head of Student & Registry Services, University College 
London Q115–212
Dr Trish Groves, Director of Academic Outreach, British Medical Journal; Dr 
Elizabeth Moylan, Senior Editor for Peer Review Strategy and Innovation, 
BioMedCentral (representing the Committee on Publication Ethics); Catriona 
Fennell, Director of Publishing Services, Elsevier (representing The Publishers 
Association); and Dr Alyson Fox, Director of Grants Management, Wellcome 
Trustl Q213–276
Monday 4 December 2107
Dr Ivan Oransky, Co-Founder, Retraction Watch, and Distinguished Writer 
in Residence, New York University Arthur Carter Journalism Institute; and 
Professor C K Gunsalus, Director, US National Centre for Professional and 
Research Ethics Q277–310
Dr Ben Goldacre, DataLab, Department of Primary Care, University of 
Oxford; Dr Simon Kolstoe, Senior Lecturer and University Ethics Adviser, 
University of Portsmouth, and Independent Chair of Hampshire A (NHS) and 
the MOD research ethics committees; and Síle Lane, Head of International 
Campaigns and Policy, Sense about Science Q311–360
Tuesday 30 January 2018
Professor Sir Bernard Silverman, Chair of Trustees, UK Research Integrity 
Office; and James Parry, Chief Executive, UK Research Integrity Office Q361–433
Dr Tony Peatfield, Director of Corporate Affairs, Medical Research Council, 
and Chairman, RCUK Good Research Conduct Network; and Dr Steven Hill, 
Head of Research Policy, Higher Education Funding Council for England Q434–496
Professor Jonathan Montgomery, Chair, Health Research Authority Q497–531
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Tuesday 6 March 2018
Professor Sir Mark Walport, Chief Executive, UK Research and Innovation 
(UKRI) Q532–615
Tuesday 8 May 2018
Mr Sam Gyimah MP, Minister for Universities, Science, Research and 
Innovation; and Dr Patrick Vallance, Government Chief Scientific Adviser 
and Head of Government Science and Engineering Profession, Government 
Office for Science Q616–693
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Published written evidence
The following written evidence was received and can be viewed on the inquiry publications 
page of the Committee’s website.
RES numbers are generated by the evidence processing system and so may not be complete.
1 Australian Research Council (RES0050)
2 Bullied into Bad Science (RES0002)
3 Carmen Helena Coxon (RES0035)
4 Cell and Gene Therapy Catapult (RES0033)
5 Cell and Gene Therapy Catapult (RES0054)
6 Collated responses from Departmental Chief Scientists (RES0048)
7 Collated responses from UUK members regarding Concordat compliance (RES0059)
8 Department for Business, Energy and Industrial Strategy (RES0057)
9 Dr Dominic Edward (RES0027)
10 Dr Gesche Huebner (RES0010)
11 Dr Hugh Llewelyn (RES0024)
12 Dr Paola Di Maio (RES0039)
13 Dr Paul Marchant (RES0042)
14 Dr Paul Taylor and Dr Daniel Barr, RMIT University, Melbourne (RES0051)
15 Dr Peter Wilmshurst (RES0025)
16 Dr Sarah Starkey (RES0018)
17 Dr Simon Kolstoe (RES0030)
18 Dr Venu Kumar (RES0012)
19 EIS (RES0013)
20 Health Research Authority (RES0040)
21 Health Research Authority (RES0047)
22 HealthWatch UK & Universities Allied for Essential Medicines UK & TranspariMED & 
Dr Simon Kolstoe (joint submission) (RES0008)
23 Innovate UK (RES0044)
24 Mathias Willumsen (RES0043)
25 Medical Research Council (RES0032)
26 Medical Research Council (RES0041)
27 Meta-Lab (RES0021)
28 Miss Tessa Burrington (RES0011)
29 Professor David J Hand (RES0028)
30 Professor Donald S Kornfeld (RES0037)
31 Professor Dorothy Bishop (RES0019)
32 Professor Marcus Munafò (RES0049)
33 Professor Patricia Murray and Raphael Lévy (RES0022)
27 Research integrity: clinical trials transparency 
34 Professor Patricia Murray and Raphael Lévy (RES0045)
35 Professor Patricia Murray and Raphael Lévy (RES0053)
36 Roger Shinton (RES0046)
37 Russell Group (RES0056)
38 Samuel Denyer and Dr Simon Peck (RES0031)
39 Sense about Science (RES0034)
40 STOPAIDS, HealthWatch UK, Universities Allied for Essential Medicines UK and 
TranspariMED (RES0036)
41 The Academy of Medical Sciences (RES0005)
42 The Royal Society (RES0014)
43 Tony Mayer, Professor Lex Bouter, and Professor Nick Steneck (RES0026)
44 TranspariMED (RES0058)
45 UK Research and Innovation (RES0055)
46 UK Research Integrity Office (RES0023)
47 UK Research Integrity Office (RES0052)
48 Universities UK (RES0020)
49 Wendy Appleby on behalf of UCL (RES0029)
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